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Thesis Abstract 
Background 
Over the last decade, adult stem cells have been proposed as novel targets of cell 
therapy. Endothelial progenitor cells (EPCs) with low aldehyde dehydrogenase activity 
(Alde-Low EPCs) are known to be suitable for the treatment of ischemic tissue whereas 
EPCs with high aldehyde dehydrogenase activity (Alde-High EPCs) are non-functional 
which cannot promote wound healing in mouse flap model. However, how Alde-Low 
EPCs contribute to wound healing is not fully understood. Moreover, stem cell-derived 
microvesicles (MVs) are capable of carrying functional mRNAs, miRNAs and proteins 
to target cells through the way of horizontal transfer and play critical role in cell-cell 
communication. Thus, extracellular vesicles are emerging as potent genetic information 
transfer agents underpinning a range of biological processes and with therapeutic 
potential. 
Purposes 
In this thesis work, the first aim is to investigate how Alde-Low EPCs as well as their 
MVs contribute to ischemic tissue repair. The second aim is to clarify the key molecules 
that are involved in the recovery from tissue damage. The third aim is to find a genetic 
tool to improve wound healing ability of Alde-High EPCs and Adipose tissue derived 
mesenchymal stem cells (AT-MSCs). 
Materials and methods 
I carried out cell culture protocol and FACS analysis to prepare target cell population 
such as EPCs, AT-MSCs. To isolate MVs, I performed ultracentrifugation. I used real 
time- polymerase chain reaction to examine the mRNA and miRNA expression, western 
blotting to evaluate protein expression levels and chromatin immunoprecipitation 
(CHIP) assay to detect interaction between DNA and protein. HIF-1α, HIF-2α as well 
as CXCR4, VEGF was knockdown in Alde-Low EPCs by short hairpin RNA (shRNA). 
In vitro and in vivo migration assay were used to check the migratory ability and 
ischemic tissue recover of target cells. Finally, data were statistically analyzed using 
Student's t-test or a one-way analysis of variance as appropriate. Data are presented as 
the mean ± SD. 
Results 
The expression level of HIF-1α and HIF-2α were found to be significant higher in Alde-
Low EPCs than in Alde-High EPCs. Interestingly, Alde-High EPCs with MVs derived 
from Alde-Low EPCs improved their ability to repair an ischemic skin flap, and the 
expression of CXCR4 and its ligand SDF-1 was significantly increased following the 
coculture. In Alde-Low EPCs, the expression of CXCR4 was suppressed by shRNA-
HIF-2α, but not shRNA-HIF-1α. CHIP assay showed that HIF-2α binds to the promoter 
region of CXCR4 gene. The CXCR4 shRNA treatment in Alde-Low EPCs almost 
completely abrogated their migratory activity to ischemic tissues. The CXCR4 
overexpression in Alde-High EPCs resulted in a partial, but significant improvement in 
their repairing ability in an ischemic skin flap. In addition, I also demonstrated that 
MVs derived from Alde-Low EPC possessed the ability to improve the homing capacity 
of AT-MSCs, resulting wound healing. Remarkably, the expression of CXCR4 is highly 
elevated in MV-transfected AT-MSCs. Moreover, AT-MSCs transfected with MVs 
showed migration at the sites of wound after their intravenous injection. Consequently, 
CD45+ inflammatory cells were successfully recruited at wound sites after the injection 
of MVs-transfected AT-MSCs. 
Discussion 
Here, I indicated that while both HIF-1α and HIF-2α have an important role in the 
recovery from ischemia, the role of HIF-2α in association with EPCs would be crucial 
during the process of ischemic tissue repair. The ischemic tissue fully recovered after 
the transplantation the MV-transfected Alde-High EPCs. In addition, I showed that 
MVs from Alde-Low EPCs provide an important potential as a therapeutic tool for AT-
MSCs. AT-MSCs that was originally unable to repair the wound when transplanted 
intravenously became to migrate at the wound sites after the incorporation of MVs 
derived from Alde-Low EPCs. The significant upregulation of CXCR4 was observed in 
AT-MSCs transfected MVs. It has been reported that SDF-1 is secreted at the site of 
skin flap dependent on degree of low oxygen tension. Thus, AT-MSCs highly 
expressing CXCR4 may be attracted and migrated to the wound sites where the 
expression of SDF-1 is upregulated. ! !
Conclusion 
I proved the crucial role of CXCR4 expressed in Alde-Low EPCs in the process of 
ischemic tissue repair. The CXCR4/SDF-1 axis, which is specifically regulated by HIF-
2α, plays a crucial role in the regulation of EPC migration to ischemic tissues. 
Additionally, MVs derived from Alde-Low EPCs are a useful source to gain the 
properties, which possess the homing capability and effective wound healing ability at 
the injured sites. 
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CHAPTER 1. INTRODUCTION  
1. Background 
1.1 Endothelial progenitor cells 
Endothelial progenitor cells (EPCs) were first isolated from adult peripheral 
blood (PB) in 1997 [1] and were shown to derive from bone marrow (BM). It has 
reported that EPCs have ability to incorporate into focus of physiological or 
pathological neovascularization [2, 3]. Moreover, a postnatal neovascularization was 
originally found to be constituted by the mechanism of angiogenesis, this process 
was controlled by in situ proliferation and migration of pre-existing endothelial cells 
[4]. Therefore, the discovery of EPCs has drastically changed the understanding of 
adult blood vessel formation.  
1.1.1. Defining endothelial progenitor cells 
Until now, the definition of an EPC has been controversial and since the 
method to isolate EPCs has been variable among investigators [5]. Several researches 
have been reported that there are two distinct types of EPCs which are called early 
and late EPCs according to the appearance sequentially [6]. Early EPCs, are 
characterized by the expression of CD45 and CD14, likely originating from 
monocytic/dendritic cells, together with some endothelial cell (EC) markers, and 
have a short lifespan of three to four weeks. Whereas, late EPCs rapidly grow out 
from mononuclear cells with a cobblestone-like morphology and are characterized by 
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EC markers such as CD31, CD34, VEGFR2, and VE-cadherin, but are negative for 
myeloid markers [6]. However, Yoder et al. have recently demonstrated that stock of 
the CD45+CD14+ cells that co-express EC markers are not endothelial progenitor 
cells but hematopoietic-derived myeloid progenitor cells [7]. Alternatively, it has 
been reported that ECs were divided into several subpopulations according to their 
clonogenic and proliferative potential [8]. They identified a population of highly 
proliferative endothelial potential–colony-forming cells, which form secondary 
colonies in human UCB. For the therapeutic potential of EPCs, the effective isolation 
of highly proliferative EPCs is centrally important for the generation of reliable and 
safe cell-based therapy. 
1.1.2 Separation of endothelial progenitor cells based on ALDH activities. 
Aldehyde dehydrogenase (ALDH) has an ancient origin and is found in all 
living organisms from Archaea and Eubacteria to eukaryotes [9, 10]. The human 
genome and expression researches revealed that there are 19 functional ALDH genes 
with a wide range of tissue expression and substrate specificity. ALDH is an enzyme 
responsible for oxidizing intercellular aldehydes [11]. This enzyme plays an 
important role in ethanol, vitamin A and cyclophosphamide metabolism [12, 13, 14]. 
Although ALDH is a cytosolic protein, its expression level can be monitored by flow 
cytometry using the fluorescent aldehyde called dansyl aminoacetaldehyde (DAAA, 
also known as Aldefluor) [15]. Several studies have been shown that hematopoietic 
stem cells, hematopoietic progenitor cells and intestinal crypt stem cells express high 
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level of ALDH [16]. Lyle Amstrong et al. reported that hematopoietic stem cells with 
high level of ALDH activity were isolated from UCB [17]. 
Nagano et al. previously demonstrated that aldehyde dehydrogenase 1 
(ALDH1) activity was a useful marker for separating functional EPCs from the 
whole endothelial colony-forming cell population [18]. Alde-Low EPCs have been 
shown to promote significantly better wound healing in a mouse model of skin flap 
ischemia. This improved wound healing was not observed with human umbilical vein 
endothelial cells (HUVECs) or Alde-High EPCs. Alde-Low EPCs were also found to 
grow faster, have a greater capacity to migrate to ischemic sites, and to be directly 
involved in new vessel formation [18].  
In addition, the separation of EPCs based on ALDH activity shows following 
advantages: 1) ALDH activity was retained in low or high in EPCs after several 
passages, 2) staining protocol was easily adopted without excessive cellular 
manipulation, 3) Adlefluor was not intercalated into DNA [18]. 
1.1.3. Functional properties of endothelial progenitor cells 
1.1.3.1 Endothelial progenitor cell mobilization 
Actually, the bone marrow is home to a stem cell niche which consists of 
fibroblast, osteoblast, endothelial cells and will provide an environment of self-
renewal and differentiation of progenitor and stem cell. Mobilization of endogenous 
EPCs from the bone marrow may be an alternative way to increase postnatal 
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neovascularization. Progenitor cells are mobilized from bone marrow into the 
circulation in response to a number of cytokines and growth factors included 
Vascular Endothelial Growth Factor (VEGF), Stromal cell Derived Factor (SDF), 
angiopoetin 1 and erthyropoetin [19]. Both VEGF and SDF-1 upregulate bone 
marrow MMP9- activity, resulting in progenitor mobilization into the vascular area 
of bone marrow [19]. In addition, tissue hypoxia appears to be a major stimulus for 
VEGF release, mostly due to the increasing of VEGF mRNA levels in response to 
hypoxia inducible factor 1 (HIF-1α) [20]. Animal studies demonstrated that the 
mobilization of EPCs is increased in response to VEGF [21]. Recently, some 
evidences have shown that erythropoietin is another cytokine that mobilization EPCs 
in vivo [22, 23]. 
Recently, EPCs circulate in the blood and possess the ability to differentiate 
into mature vascular endothelial cells (ECs), contribute to new vessels, and to aid in 
the regeneration of impaired blood vessels [24, 25]. 
1.1.3.2. Endothelial progenitor cells adhesion 
In order to participate in vascular repair, EPCs need to adhere to the 
vasculature at the site of ischemia or injury. Intergrins have been demonstrated to 
mediate adhesion of endothelial cells. In details, ß-1-intergrins are expressed on the 
surface of endothelial cells while ß-2-intergrins are expressed on hematopoietic stem 
cells [26]. ß-2-intergrins are also expressed on the surface of EPCs derived from 
peripheral blood and required for EPC adhesion to endothelial cells and trans-
! 5!
endothelial migration in vitro [27]. 
1.1.3.3. Endothelial progenitor cell chemotaxis and migration 
In order to response the tissue injury and ischemia, a number of EPCs are 
released, it is necessary to have a sufficient concentration of chemo-attractant factors 
to facilitate recruitment to the injured site. VEGF has been demonstrated to act as a 
chemo-attractant factor to EPCs [28]. In addition, SDF-1 has been shown to be an 
important chemotactic factor and stimulates recruitment of EPCs to ischemic tissue 
[29, 30]. Recent studies have shown that SDF-1 plays an important role in the 
regulation of a variety of cellular functions of EPCs such as cell migration, 
proliferation, and survival. Interestingly, CXCR4, a transmembrane-spanning G 
protein-coupled receptor, is the receptor for SDF-1 and is the most important homing 
gene of EPCs [30]. 
1.1.3.4. Endothelial progenitor cells and angiogenesis 
It has been suggested that bone marrow-derived EPCs localize within the site 
of EC damage and induce revascularization [31]. Indeed, after EPCs pass from bone 
marrow to peripheral circulation, they migrate to the sites at which endothelial injury 
and a hypoxic state occur within the tissue. Once there, EPCs promote angiogenesis 
with or without directly contributing to the formation of vessels in response to the 
physiologically distinct environment [27, 32, 33] (Figure 1).  
The mechanisms by which EPCs are able to induce recovery in damaged 
vessels and tissues are not fully understood. Several studies have demonstrated that 
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EPC infusion exerts protective effects on hindlimb ischemia, myocardial infarction, 
and glomerular diseases in animal models [33]. Despite these benefits, the 
regenerative effects of EPC-based cell therapy remain to be clarified: whether EPCs 
directly contribute to and are incorporated in revascularization [34, 35] or whether 
they favor reciprocal interaction due to a paracrine mechanism that occurs within 
ischemic tissues [36]. Recently, many studies have suggested that cells may also 
communicate through circular membrane fragments named microvesicles (MVs) 
[37]. It has been hypothesized that MVs released from EPCs may play an important 
role in the cell-to-cell communication of cytokines, growth factors, surface receptors, 
and nucleotides [38, 39]. 
In addition, hypoxia is an important point of homeostatic mechanisms of the 
regulation of angiogenesis [40]. It is reported that Hypoxia-inducible factor (HIF) is 
an α,β-heterodimeric transcription factor that mediates cellular responses to low 
oxygen concentration via the transcriptional activation of specific genes involved 
angiogenesis. Study of the HIFs pathway has potential use for the treatment of 
ischemic disease and cancer [41]. 
1.1.4. Perspective for future direction. 
Although there are many encouraging studies regarding the therapeutic 
potential of EPCs, several issues currently needed to be studied in the way of their 
wide clinical application. Strategies need to be developed to enhance the number of 
EPCs as well as source of cells such as bone marrow, umbilical cord blood, umbilical 
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cord vein and peripheral blood. Moreover, further examination of the biology of 
EPCs need to be determined about the nature of the mobilizing, migratory and 
homing signal, and the mechanism of incorporation into the target tissues. I listed 
some issueses which need to standardize in order to apply EPCs for treatment of 
tissue ischemia, and vessel repair or angiogenesis. Despite these hurdles, the 
application for EPC-based therapy for tissue ischemia and blood vessel repair 
appears promising. Genetic engineering of EPCs may provide an important strategy 
to enhance EPC mobilization, survival, engraftment, and function, thereby rendering 
these cells efficient therapeutic modalities for ischemia or cardiovascular disease. 
1.2. Mesenchymal stem cells 
The non-hematopoietic stem cells in bone marrow was first discovered by the 
study of the German pathologist Cohnheim. His research showed the capacity of 
bone marrow that can be used as the source of fibroblast that deposit collagen in the 
process of wound repair [42]. After separation by density gradient centrifugation, 
human mesenchymal stem cells (MSCs) are typically isolated from the mononuclear 
layer of the bone marrow [43]. The mononuclear cells are cultured in medium with 
10% fetal bovine serum, and the MSCs adhere to the tissue culture plastic. Some 
hematopoietic cells also adhere, but after few passages in culture these are washed 
away. MSCs have now been isolated from various sites other than the bone marrow, 
including adipose tissue, amniotic fluid, periosteum, and placenta [44, 45, 46, 47]. 
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Among the adult stem cells, MSCs have been considered as an excellent material for 
regenerative medicine because of their self-renew ability, broad differentiation 
potential, wide accessibility and lack of ethical concerns [48, 49]. In addition to 
multi-potent potential, MSCs can regulate immune/ inflammatory processes making 
these cells more attractive for the therapy of many disorders [50, 51, 52].  
Adipose tissue-derived MSCs (AT-MSCs) are expected as more reliable cell 
source for regenerative medicine because that can be isolated by minimally invasive 
fashion for the patient compared to other MSCs  [49]. There are multi-steps for 
MSCs to engraft to the appropriate sites after the delivery from some particular 
organs where MSCs are located. It is especially important to investigate the MSC 
properties in each situation in our body in the multi-steps, such as extravasations, 
homing and engraftment of MSCs. However, few studies have provided insight into 
the mechanisms of MSCs to improve the therapeutic efficacy. 
1.3. Microvesicles (MVs) 
Extracellular vehicles have been considered as bioactive mediators of cell-cell 
interaction. These vehicles are categorized into exosomes and shedding vehicles. The 
mixed populations of exosomes and shedding vehicles are collectively known as 
microvesicles (MVs). MVs are a heterogeneous population of membrane vesicles 
that are shed or bud from the cell membrane (Figure 2). Since they shed directly from 
the plasma membrane, one could expect the composition of shedding vesicles to be 
comparable to the membrane composition of the cells of origin [53]. Recently, MVs 
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can be isolated using ultracentrifugation (Figure 3). MVs contain surface receptors, 
bioactive molecules such as proteins and lipids as well as mRNAs and microRNAs 
[37, 38]. Therefore, those RNAs in MVs could play a role in the exchange of genetic 
material between stem cells and target cells as well as the changing of biological 
activity by proteins or lipids. Since, MVs seem to be nature's way to deliver 
biological items, they hold great potential as a novel class of drug delivery systems 
[53]. 
It has been shown that MVs derived from EPCs activated an angiogenic 
program in endothelial cells by a horizontal transfer of mRNA [38]. To develop a 
unique gene therapy, it would be necessary to investigate therapeutic power of MVs 
derived from many types of stem cells in future. 
 
2. Abbreviations 
ALDH Aldehyde dehydrogenase  
ATMSCs Adipose tissue derived mesenchymal stem cells 
b-FGF  basic Fibroblast growth factor 
BM  Bone marrow 
BSA  Bovine serum albumin 
CCL  chemokine (C-C motif) ligand 
cDNA  Complementary DNA 
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CHIP  Chromatin immunoprecipitation 
ColIV  Collagen type IV 
CXCR4 C-X-C chemokine receptor type 4 
DFO  Desferrioxamine 
ECs  Endothelial Cells 
EPCs  Endothelial Progenitor Cells 
FACS  Fluorescence-activated cell sorting 
FBS  Fetal bovine serum 
GFP  Green fluorescent protein 
Glut-1  Glucose transporter 1 
HIF  Hypoxia inducible factor 
HUVEC Human umbilical vein endothelial cells 
IMDM Iscove's modified Dulbecco's medium 
IL6  Interleukin 6 
MSCs  Mesenchymal stem cells 
miR  Micro-RNA 
mRNA messenger RNA 
MVs  Microvesicles 
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PBS  Phosphate-buffered saline 
PB  Peripheral blood 
RT-PCR Reverse transcription-polymerase chain reaction 
shRNA Short hairpin RNA 
SDS-PAGE Sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
SDF-1  Stromal cell derived factor 1  
TGF  Transforming growth factor 
UCB  Umbilical cord blood 
VCAM-1 Vascular cell adhesion molecule 1 
VEGF  Vascular endothelial growth factor 
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3. Aim of study 
Our group has clearly demonstrated that Alde-Low EPCs are suitable for the 
treatment of ischemic tissue whereas Alde-High EPCs cannot promote wound 
healing in mouse flap model [18]. However, how Alde-low EPCs contribute to 
wound healing is not fully understood. I took note of the fact that MVs are capable of 
transferring bioactive molecules including mRNAs, miRNAs and proteins to 
recipient cells and play critical role in cell-cell communication. Therefore, Alde-Low 
EPC-derived MVs could be expected as potent genetic information transfer agents 
underpinning a range of biological processes and with therapeutic potential. In my 
PhD work, I have following purposes as listed bellow: 
1. Investigate a functional role of Alde-Low EPCs to contribute into ischemic 
tissues 
2. Find key molecules involved in the wound healing process in Alde-Low EPCs 
3. Examine a function role of Alde-Low EPCs-derived microvesicles to promote 
the migration and wound healing ability of Alde-High EPCs and AT-MSCs. 
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Chapter II. Materials and Methods 
 
1. The preparation of EPCs isolated by ALDH activity 
Human full-term UCB samples (n = 3) were collected from umbilical cord 
veins with the permission of the local ethics authorities at the University of Tsukuba. 
Mononuclear cells from human UCB were separated by density gradient 
centrifugation after the depletion of hematopoietic cells. CD45−/CD31+ cells were 
then sorted using anti-CD45 and anti-CD31 antibodies (BioLegend) with a MoFlo 
(MoFlo XDP; Beckman Coulter). Cells were plated on a 25-cm2flask (Sumitomo 
Bakelite) with Iscove's modified Dulbecco's medium (IMDM; Life Technologies) 
with 10% fetal bovine serum (FBS; Life Technologies), 2$mg/mL L-glutamine (Life 
Technologies), 10$ng/mL hb-FGF (PeproTech), and 0.1% (vol/vol) penicillin–
streptomycin (100$U/mL penicillin, 0.1$mg/mL streptomycin; Life Technologies) as 
described previously [18]. After 7 days, adherent cells began to grow and rapidly 
evolve to form colonies with tightly compact morphologies. Subsequently, DiI-Ac-
LDL+/CD31+ cells were sorted (DiI-Ac-LDL; Molecular Probes) with a MoFlo. The 
culture of the sorted cells was continued in IMDM/10% FBS supplemented with b-
FGF [18]. These cells displayed an EC-like morphology. Their ALDH activity was 
analyzed with an ALDEFLUOR® (StemCell Technologies). The EPCs were then 
sorted into two fractions based on their level of ALDH expression (Alde-High EPCs 
and Alde-Low EPCs) using the MoFLo. The EPCs were labeled with the lentivirus-
! 14!
green fluorescent protein (GFP) (Sigma-Aldrich) in order to use in the experiment of 
in vivo migration assay. Frozen cell stocks were prepared using the CELLBANKER 
(ZENOAQ) solution and stored in liquid nitrogen. For hypoxic stimuli, EPCs were 
treated with or without desferrioxamine (DFO: 100$µM) for 6$h or cultured under 
hypoxic conditions (1% O2) for 6$h. 
2. Microvesicle (MV) preparation and transfection protocol 
MV isolation was performed according to the method reported by Deregibus 
et al. [34] with some modifications. After EPCs reached confluence, the culture 
medium of EPCs was changed to serum-free EBM-2 (Lonza, Basel, Switzerland) 
supplemented with 0.25% BSA (Sigma-Aldrich, St. Louis, MO). After 12 h, 
supernatants were collected and centrifuged at 1,000 x g for 20 minutes to remove 
debris and ultracentrifuged at 100,000 x g (Beckman Coulter Optima L-100K) for 60 
min at 4oC. MV pellets were washed with PBS and re-centrifuged at 100,000 x g for 
60 min at 4oC. MVs were purified using a cell sorter (MoFlo XDP) according to the 
expression of EPC-specific markers. The antibodies used were PE–labeled anti-
CD31, APC–labeled anti-CD45 (BioLegend, San Diego, CA) and FITC-labeled anti-
CD105 (Serotec, Oxford, UK). The protein content of MVs was quantified using the 
Bradford method (BioRad). MVs were stained using the PKH26 red fluorescent cell 
linker kit for general cell membrane labeling (PKH26GL-1KT -100M0612- Sigma-
Aldrich) or PKH67 green fluorescent cell linker kit for general cell membrane 
labeling (MINI 67-1KT - SLBB7129- Sigma-Aldrich). After the staining, MVs were 
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washed twice by PBS using ultracentrifugation before incubation with recipient cells. 
The labeled MVs were mixed in culture medium and incubated with Alde-High EPCs 
or AT-MSCs (14.5 µg/ 500,000 cells). The efficiency of transfected cells was 
examined using FACSs according to the fluorescent signal after 12 h of MV 
transfection. 
3. Quantitative RT-PCR 
 RNA was isolated from cultured cells or MV samples using an RNeasy Mini 
Kit (Qiagen). Total RNA (1$µg) was reverse transcribed using an RT-PCR Kit 
(TOYOBO). Complementary DNA (cDNA) was analyzed using a GeneAmp 7500 
Fast Real-Time PCR System (Life Technologies) using the SYBR Green reagent 
(TOYOBO). The expression levels of the target genes were analyzed with the ΔΔCt 
method. The primers used for the polymerase chain reaction (PCR) were as follows: 
VEGF (5′-AGATGAGCTTCCTACAGCACAAC; 3′-
AGGACTTATACCGGGATTTCTTG), CXCR4 (5′-
CTGTGACCGCTTCTACCCCAATGACTT; 3′-
CCAAGGAAAGCATAGAGGATGGGGTTC), KDR (5′-
AGTGTGGAGGACTTCCAGGGAGGAAAT; 3′-
GGCCAAGCTTGTACCATGTGAGGTTCT), SDF-1 (5′-
TGAGAGCTCGCTTTGAGTGA; 3′-CACCAGGACCTTCTGTGGAT), VCAM-1 
(5′-GTAAGCTGCAAGGTTCCTAGCGTGT; 3′-
GCTGACCAAGACGGTTGTATCTCTG), Glut-1 (5′-
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ACTGCTCAAGAAGACATGGAGAC; 3′-ATTTACAAGTTGGCTTGTCCAGA), 
TGF-β (5′-AGAGCTCCGAGAAGCGGTACCTGAACCC; 3′-
GTTGATGTCCACTTGCAGTGTGTTATCC), HIF-1α (5′-
TTACCGAATTGATGGGATATGAG; 3′-TCATGATGAGTTTTGGTCAGATG), 
ColIV (5′-AGGGCCAGCCTGGCCTGCCAGGACTTCC; 3′-
TCACCCTTAGAGCCTGTGATTCCTGGAG), CoIV (5'-
AGGGCCAGCCTGGCCTGCCAGGACTTCC; 3'-
TCACCCTTAGAGCCTGTGATTCCTGGAG), hCCL2 (5’-
ATGAAAGTCTCTGCCGCCCTTCTGTG; 3’- 
TCAAGTCTTCGGAGTTTGGGTTTGCTT), hCCL5   (5’- 
GAGGATTCCTGCAGAGGATCAAGACAG, 3- 
TCCAAAGAGTTGATGTACTCCCGAACC),  
hCCL3  (5′-ACTGCCTGCTGCTTCTCCTACA- 3′-
AGGAAAATGACACCTGGCTGG), 
 and β-actin (5′-GTGCGTGACATTAAGGAGAAGCTGTGC; 3′-
GTACTTGCGCTCAGGAGGAGCAATGAT). 
4. RT-PCR for miRNAs 
The miRNA quantification using the Tagman miRNA assays was determined 
by two-step RT-PCR following the manufacture’s protocol. The real time was 
performed using the Tagman miRNA reverse transcription kit and the PCR step was 
performed using Tagman universal PRC master mix II, with UNG. The primers for 
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miRNAs include hsa-miR-126 (P140423-005 G01), has-miR296 (P140625-000-E03) 
and RNU48 (P141013-007 E07) (Applied Biosystems). 
5. Animal studies 
C57BL/6J male mice (8 to 10 weeks) were purchased from Japan SLC, Inc. 
The mice were treated in accordance with the National Institutes of Health (NIH) 
Guide for the Care and Use of Laboratory Animals. All animal studies were 
performed after receiving approval from the Institutional Animal Experimental 
Ethics Committee of the University of Tsukuba. 
The mice were anesthetized with Avertin and the back skin was shaved. To 
create the ischemic region, a rectangular-shaped incision (3$×$2$cm) was made on the 
dorsal skin with only the proximal end remaining attached to the circulation, thus 
creating a proximal to distal ischemic gradient [34]. Immunosuppression was induced 
by an intraperitoneal injection of cyclosporin-A (20$mg/kg/day) (Wako) from 2 days 
before the assay [8]. Following surgery, GFP-labeled EPCs or AT-MSCs with or 
without MVs transfection (5$×$105 cells/mouse) were injected into the tail vein. After 
7 days of the surgery/injection, mice were sacrificed and the image of necrotic skins 
was captured. The necrotic areas and total area of skin flap were measured. Then the 
necrotic areas were divided to total area of skin flaps. The results are expressed as the 
average area of necrotic skin as a percentage of the total flap area. An in vivo 
migration assay was carried out at 24$h after the GFP labeled EPCs or AT-MSCs plus 
MVs injection. To detect GFP-labeled EPCs, AT-MSCs plus MVs, frozen flap skin 
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tissue sections were analyzed by a fluorescent microscopy to detect fluorescent 
signals. The results are expressed as the average number of cells that were seen as per 
high-power field. 
6. Western blotting 
Sample cells, which were treated with or without DFO (100$µM) for 6$h, were 
harvested and suspended in low salt buffer [10$mM HEPES, 10$mM KCl, 1$mM 
dithiothreitol, 0.1$mM EDTA, protease inhibitor cocktail (PIC; Roche Diagnostics), 
and 1% Nonidet P-40] and nuclear pellets were collected by centrifugation. The 
nuclear pellets were suspended in high salt buffer (20$mM HEPES, 400$mM NaCl, 
1$mM dithiothreitol, and 1$mM EDTA, PIC); after centrifugation, a nuclear extract 
was obtained. These nuclear extract samples were separated on 10% sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) gel by electrophoresis and 
transferred onto PVDF membrane (Millipore). An immunoblotting analysis was 
performed as previously described [18]. Anti-human HIF-2α antibody [56], anti-
human HIF-1α antibody (Novus Biologicals), and anti-Lamin B antibody (Santa Cruz 
Biotechnology, Inc.) were used for the immunoblotting assay. Horseradish 
peroxidase (HRP)-conjugated goat anti-rabbit IgG (Invitrogen) or goat anti-mouse 
IgG (Life Technologies) was used as the secondary antibody, and enhanced 
chemiluminescence (GE Healthcare Biosciences) was used for detection. 
7. Overexpression and the shRNA treatment of target genes 
The Alde-High EPCs were infected using cell-free retroviral supernatant from 
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PT67 packaging cells (Clontech) producing MSCV-hCXCR4-IRES-EGFP or 
MSCV-IRES-EGFP (control virus) with 8$mg/mL polybrene. After 24$h, the medium 
was changed to fresh virus-free medium, and cells were expanded for 4–6 days. The 
GFP-positive cells were then sorted using a MoFlo and then expanded for the 
subsequent experiments. MSCV-hVEGF-PGK-puro retroviruses were used to 
promote VEGF overexpression in Alde-High EPCs. Puromycin (2$µg/mL) was used 
to select infected EPCs. 
To downregulate the target genes, I used the shRNA MISSION lentiviral 
transduction system (Sigma-Aldrich) according to the manufacturer's protocol. The 
infected cells were selected with a puromycin resistance method. Puromycin 
(2$µg/mL) was used to select the infected EPCs. 
8. Chromatin immune-precipitation assay 
For each assay, 5$×$106 Alde-Low EPCs were fixed with 1% formaldehyde for 
10$min at room temperature. After being washed with PBS containing 1$µM PIC 
(Roche Diagnostics), the EPCs were treated with hypotonic solution (5$mM HEPES, 
85$mM KCl, 0.5% NP-40, and 1$µM PIC). Nuclei were collected after centrifugation 
at 14,000g for 5$min, then lysed with a lysis buffer (50$mM Tris-HCl, [pH 8.1], 
10$mM EDTA, 1% SDS, and 1$µM PIC). After the fragmentation of DNA by 
sonication, immunoprecipitation reactions were performed using a rotating mixer at 
4°C with 1$µg/mL anti-HIF-1α antibody or anti-HIF-2α antibody (Novus 
Biologicals). Normal mouse IgG or rabbit IgG was used as a negative control to 
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verify the specificity of the reaction. After incubation with the antibody, reaction 
mixtures were incubated with preblocked protein A agarose beads (Calbiochem) at 
4°C for 1$h and the precipitated complexes were collected by centrifugation at 3,000g 
for 5$min. These complexes were washed three times with the wash buffer (0.25$mM 
LiCl, 1% NP-40, 1% sodium deoxycholate, 1$mM EDTA, and 10$mM Tris-HCl [pH 
8.1]) and eluted from the protein A agarose beads with the elution buffer (1% SDS 
and 0.1$M NaHCO3). DNA–protein complexes were denatured by incubation at 65°C 
for 4$h. DNA fragments were purified with phenol/chloroform, and resuspended in 
the TE buffer. The following primers were used for the PCR: forward, 5′-
TTCTTCAACCTAATTTCTGATTCGTGC-3′ and reverse, 5′-
ATCACTAGGAACTTGCACAGAATCAC-3′. 
9. In vitro migration transwell assay 
This assay was perform follow the protocol which was originally introduced 
by Boyden with some modification [57]. EPCs (5$×$104 cells) were seeded onto 
transwell (6.5$mm, 8$µm pore; BD Biosciences) in IMDM supplemented with 0.5% 
FBS. IMDM/0.5% FBS with recombinant human SDF-1 (200$ng/mL; R&D Systems) 
was added to the lower chamber. The assays were performed under different oxygen 
tensions (20% or 5%) for 6$h, and non-migrated cells were wiped away from the top 
surface of the membrane. Cells that adhered to the undersurface of the membrane 
were stained with Diff-Quik staining solution (International Reagents) and then 
counted using an inverted microscope. 
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10. Preparation of MSCs derived from adipose tissue 
Human adipose tissue samples (n = 3) of healthy donor were collected after 
informed consent with permission from the local ethics authorities at the University 
of Tsukuba. The protocol for isolation of AT-MSCs was follow from protocol [37]. 
Tissues were minced and treated with 10% collagenase 0.1% (Nitta Gelatin, Osaka, 
Japan) in 20% fetal bovine serum (FBS; Hyclone SH30396.03, South Logan, UT) 
and 70% phosphate buffer saline containing 0.1% (vol/vol) penicillin-streptomycin 
(Invitrogen 15140; 100 U/mL penicillin, 0.1 mg/mL streptomycin, Carlsbad, CA) at 
37oC for 40 min.  A single cell suspension was made using a syringe and 18G needle, 
then filtered through a cell strainer (Falcon; pore size 100 µm, BD Bioscience, San 
Joe, CA), followed by centrifugation at 1500 rpm at 10oC for 5 min. Cells were 
cultured in Iscove's Modified Dulbecco's Medium (IMDM; Invitrogen 12200-069), 
10% FBS, 2 mg/mL L-glutamine (Invitrogen; 25030), 5 ng/mL recombinant human 
b-FGF (Peprotech; 064-04541, London, UK) at 37°C in 5% CO2 and a humidified 
atmosphere. After 1 day, medium containing non-adherent cells was removed and 
replaced with fresh medium. Frozen cell stocks were prepared using Cell Banker 
solution (ZENOAQ, Koriyama, Japan) and stored in a −80o C freezer and liquid 
nitrogen for further experiments. 
11. In vitro differentiation assay of MSCs 
To induce osteogenic differentiation, 5x104 cells were treated with osteogenic 
differentiation medium in 4-well plates (Nalge Nunc, Rochester, NY) for 4 weeks. 
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The osteogenic differentiation medium consisted of IMDM supplemented with 1% 
FBS, 0.1 mM dexamethasone (Sigma–Aldrich), 10 mM β-glycerol-2-phosphate 
(Sigma–Aldrich), 0.2mM ascorbic acid (Sigma Aldrich) and 50 ng/ml of human EGF 
[13, 20]. The culture medium was replaced with fresh medium once or twice a week. 
The mineralized matrix was evaluated by Von Kossa staining and Alizarin red 
staining as described previously [57, 58].  
Adipogenic differentiation was induced in 4-well plates for 4 weeks by 
adipogenic differentiation medium consisting of IMDM supplemented with 10% 
FBS, 0.1 mM dexamethasone (Sigma–Aldrich), 0.5 mM 3-isobutyl-1-methylxanthine 
(IBMX; Sigma–Aldrich), 2 mg/ml insulin (Wako) and 0.1 mM indomethacine 
(Sigma–Aldrich). The culture medium was replaced with fresh medium once or twice 
a week. Cultured cells in adipogenic differentiation medium were fixed with 10% 
formaldehyde and stained with Oil-Red O solution (Muto Pure Chemicals, Tokyo, 
Japan) for 30 min at 42oC. After the staining, cells were dissolved with 4% IGEPAL 
CA630 (Sigma–Aldrich) in isopropanol and the absorbance was measured at 480 nm.  
12. In vitro migration scratch assay with mytomicin C 
The in vitro migration assay was performed according to the modified method 
reported by Chun-Chi Liang et all. [59]. Briefly, AT-MSCs (1.5x105 cells) were 
seeded on 4-well dish (BD Biosciences) in IMDM supplemented with 10% FBS. 
After cells reach confluent monolayer, cells were inactivated by mytomicin C 
(Sigma) at concentration 10 µg/ml for 3 h. Cells were washed three times with PSB 
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and scratch wounds of 1 mm width were generated with a 200 µm pipette tip. Cells 
were wash 2 times with PBS softly to remove all floating cells. AT-MSCs were then 
transfected with or without MVs derived from Alde-low EPCs, and cultured for 16 h. 
Representative pictures were captured to track migration of individual cells in the 
leading edge of the scratch. Migration distance (µm) was calculated by software 
ImageJ. 
13. Histological analysis 
Inflammatory cells in the ischemic tissue were examined by 
immunohistochemical staining with PE-labeled anti-CD45 (30F11, BD Pharmingen). 
The number of CD45-positive cells was counted in each field. The presented data are 
the average of ten fields per section. 
14. Statistical analysis 
Data were statistically analyzed using Student's t-test or a one-way analysis of 
variance as appropriate. Data are presented as the mean ± standard deviation. 
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Chapter III.  A Chemokine Receptor, CXCR4, Which Is Regulated by 
Hypoxia-Inducible Factor 2α, Is Crucial for Functional Endothelial 
Progenitor Cells Migration to Ischemic Tissue and Wound Repair 
 
1. Purpose 
EPCs have the ability to form new blood vessels and protect ischemic tissues 
from damage. We previously reported that EPCs with low activity of aldehyde 
dehydrogenase (Alde-Low EPCs) possess the greater ability to treat ischemic tissues 
compared with Alde-High EPCs. However, the mechanisms by which EPCs are able 
to induce recovery in damaged vessels and tissues are not fully understood. 
Recently, many studies have suggested that cells may also communicate 
through circular membrane fragments named microvesicles (MVs). It has been 
hypothesized that MVs released from EPCs may play an important role in the cell-to-
cell communication of cytokines, growth factors, surface receptors, and nucleotides. 
The aim of this study was to investigate how functional EPCs (Alde-Low 
EPCs) as well as their MVs contribute to ischemic tissue repair and to clarify the key 
molecules that are involved in the recovery from tissue damage. 
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2. Results 
2.1. Alde-High EPCs with MVs derived from Alde-Low EPCs possess the ability 
to repair wounds 
Alde-High EPCs and Alde-Low EPCs were derived from the same UCB 
samples and separated with fluorescence-activated cell sorting on the basis of ALDH 
activity, as previously reported. The ratio of Alde-High EPCs was 24.6% ± 9.4%, 
whereas the ratio of Alde-Low EPCs was 37.3% ± 1.5% [18]. To characterize the cell 
types, we investigated whether Alde-High EPCs could attain similar characteristics to 
Alde-Low EPCs through exterior influences. 
MVs are released from the cell surface and are able to transfer mRNAs and 
miRNAs between cells. The release of MVs from the cell surface increases cell 
growth activity, reduces apoptosis, and protects from cellular injury [60, 61]. 
I first isolated MVs derived from Alde-Low EPCs (Fig. 3) by 
ultracentrifugation 2 times, then MVs were mixed in culture medium and incubated 
with Alde-High EPCs. In contrast to Alde-Low EPCs, Alde-High EPCs have not 
been shown to promote wound healing. 
The isolation of MVs from Alde-Low EPCs was performed with reference to 
previous reports and evaluated by examining the expression of angiogenic genes in 
the MVs. As shown in Fig. 4C, PKH26-labeled MVs, which were isolated from 
Alde-Low EPCs, were incorporated in Alde-High EPCs by coculture for 12$h. The 
expression of MVs in relation to the angiogenic genes was analyzed; most of the 
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examined genes were positively expressed similar to those in their parent cells (Alde-
Low EPCs) (Fig. 4B). 
I then examined the expression of angiogenic genes in Alde-High EPCs that 
were cocultured with MVs derived from Alde-Low EPCs. The expression of the 
CXCR4 chemokine receptor, which is important for migration at the wound site, and 
its ligand SDF-1, were found to be highly elevated in the MVs transfected Alde-High 
EPCs. 
Angiogenic factor, VEGF, and adhesion molecules, Col IV and VCAM-1, 
were also upregulated in the transfected Alde-High EPCs in comparison to the 
nontransfected Alde-High EPCs (Fig. 5). An in vivo assay using a mouse model of 
skin flap ischemia clearly demonstrated that transfected Alde-High EPCs had a 
wound repair ability that was similar to that of Alde-Low EPCs (necrotic area: PBS, 
40.6%$±$8.2%; Alde-Low EPCs, 1.3%$±$2.3%; Alde-High EPCs, 39.0%$±$8.9%; 
Alde-High EPCs with MVs, 4.8%$±$6.3%;! Fig.! 6! A,! B). Interestingly, HUVEC-
transfected Alde-Low EPC-derived MVs showed less recovery from necrosis than 
the transfected Alde-High EPCs (data not shown). 
Taken together, these results indicate that Alde-High EPCs possess a similar 
phenotype to Alde-Low EPCs from the point of the functional characteristics of 
EPCs in relation to neovascularization, suggesting that Alde-High EPCs would be a 
useful tool for investigating the molecular mechanisms underlying the angiogenic 
properties of Alde-Low EPCs. 
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2.2. HIF-2α, but not HIF-1α is a crucial factor for the expression of CXCR4 in 
EPCs 
Our group previously found that under hypoxic conditions the expression of 
HIF-1α and HIF-2α were highly upregulated in Alde-Low EPCs in comparison to 
Alde-High EPCs [18]. To investigate the differences in the roles of these HIF factors 
in EPCs, the shRNAs of the HIFs were used to differentially decrease their 
expression. A western blotting analysis clearly showed that HIF-1α and HIF-2α were 
restrained by their respective shRNAs at levels of below 20% (Fig. 7 A, B). We 
subsequently examined the expression levels of the target genes of HIF-1α and HIF-
2α in the HIF shRNA-treated cells after exposure to 1% O2 for 6$h (Fig. 7C). VEGF 
mRNA expression was suppressed by both HIF-1α shRNA and HIF-2α shRNA 
[Alde-Low EPCs with HIF-1α shRNA, 0.51$±$0.11-fold decrease, P$<$0.05 (n$=$3); 
Alde-Low EPC with HIF-2α shRNA, 0.23$±$0.28-fold decrease, P$<$0.05 (n$=$3)]. Of 
note, CXCR4 mRNA expression was suppressed by HIF-2α shRNA, but not by HIF-
1α shRNA [0.06$±$0.03-fold decrease, P$<$0.01 (n$=$3)]. Collectively, the results 
indicate that HIF targeting genes are regulated differently by HIFs in EPCs and that 
further experiments are required to elucidate the mechanisms that underlie the 
differences in their regulation in EPCs. 
To investigate how HIFs are involved in the functional role of Alde-Low 
EPCs in vivo, I analyzed the mouse model of skin flap ischemia. Seven days after the 
injection of Alde-Low EPCs into the tail vein, there was a reduction in the size of the 
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necrotic area (2.5%$±$5.3%,!Fig. 8 A, B). However, Alde-Low EPCs with HIF-1α 
shRNA showed a reduced ability to repair the necrotic area [13.2%$±$2.81%, P!<!0.05 
(n$=$3) vs. control Alde-Low EPC]. Remarkably, when Alde-Low EPCs with HIF-2α 
shRNA were injected, wound repair was significantly impaired and large necrotic 
areas were observed [34.1%$±$5.15%, P!<!0.01 (n$=$4) vs. control Alde-Low EPCs]. 
Further supporting this finding, a significantly lower number of GFP-labeled HIF-2α 
shRNA Alde-Low EPCs was detected at the site of the skin flap in comparison to 
mice that were injected with HIF-1α shRNA Alde-Low EPCs [control Alde-Low 
EPCs, 76.8$±$5.9; Alde-Low EPCs with HIF-1α shRNA, 61.2$±$4.6, P!<!0.05 (n$=$3); 
Alde-Low EPCs with HIF-2α shRNA, 13.5$±$14.6 cells per field, P!<!0.01 (n$=$3),!Fig.! 8! C]. These results strongly suggest that CXCR4 is a crucial factor for cell 
migration and that in EPCs, the expression of CXCR4 is regulated by HIF-2α. 
Finally, we examined how the expression of CXCR4s is regulated in EPCs by HIF-
2α using a chromatin immunoprecipitation (CHIP) assay. The CHIP assay clearly 
demonstrated that HIF-2α, but not HIF-1α binds to CXCR4 promoter region, 
indicating that HIF-2α is a key factor in the regulation of CXCR4 expression in Alde-
Low EPCs (Fig.!8!D). HIF-1α may also be involved in the migratory activity of EPCs; 
however, the effect was less than that of HIF-2α, which suggests the possible 
existence of a separate mechanism that is related to EPC migration from the 
CXCR4/SDF-1 axis. 
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2.3. CXCR4 is a crucial factor in the migration of EPCs 
I found that CXCR4 expression is profoundly regulated by HIF-2α, whereas 
VEGF expression is regulated by both HIF-1α and HIF-2α in Alde-Low EPCs. I next 
investigated the functional associations of CXCR4 and VEGF with the repair of 
ischemic tissue in the mouse model of skin flap ischemia. Alde-Low EPCs with 
CXCR4 shRNA or VEGF shRNA were prepared and used to examine the 
involvement of these genes in EPC migration. 
CXCR4 mRNA expression in Alde-Low EPCs with CXCR4 shRNA showed a 
0.25$±$0.01-fold decrease [P!<!0.01 (n$=$3)] in comparison to the control under 
normoxic conditions [1.00$±$0.59-fold (n$=$3)] and a 0.33$±$0.01-fold decrease 
[P!<!0.01 (n$=$3)] under hypoxic conditions [control: 2.39$±$0.43-fold (n$=$3)]. On the 
other hand, VEGF mRNA expression in Alde-Low EPCs with VEGF shRNA showed 
a 0.37$±$0.09-fold decrease [P!<!0.01 (n$=$3)] in comparison to the control under 
normoxic conditions [control: 1.00$±$0.30-fold, (n$=$3)] and a 1.55$±$0.18-fold 
decrease [P!<!0.01 (n$=$3)] under hypoxic conditions [control: 3.82$±$0.37-fold, 
(n$=$3)] (Fig.! 9). The expression levels of the other HIFs target genes (Glut-1 and 
KDR) in the Alde-Low EPCs with these CXCR4/VEGF shRNAs did not differ from 
the control. 
I then investigated the involvement of these genes in the repair of ischemic 
tissue in our mouse model of skin flap ischemia. Alde-low EPCs that were 
transfected with CXCR4 shRNA totally lost their ability to repair the ischemic sites. 
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In contrast, Alde-low EPCs that were transfected with VEGF shRNA showed a slight 
suppression in their ability to repair ischemic tissue [necrotic area: control Alde-Low 
EPCs, 3.0%$±$5.1%; Alde-Low EPCs with VEGF shRNA, 21.2%$±$9.1%; Alde-Low 
EPCs with CXCR4 shRNA, 35.5%$±$3.5% (n$=$3 in each)] (Fig.!10!A,!B). 
CXCR4 is a chemokine receptor that is strongly associated with the migration 
of stem cells, including EPCs. To analyze the involvement of CXCR4 in the 
migration of EPCs, I performed two assessments. First, the number of migrated cells 
at ischemic sites was assessed in response to Alde-Low EPCs with GFP transfected 
with each shRNA (Fig.! 10! C). I observed a 75% reduction in the number of GFP-
positive cells following the injection of Alde-low EPCs with CXCR4 shRNA in 
comparison to the control [control Alde-Low EPCs, 76.8$±$5.9 cells per field; Alde-
Low EPCs with CXCR4 shRNA, 16.3$±$10.3 cells per field, P!<!0.01 (n$=$3)]. When 
transfected with VEGF shRNA, the number of GFP-positive cells was not 
significantly different from that in the control Alde-Low EPCs [control Alde-Low 
EPCs, 76.8$±$5.9 cells per field; Alde-Low EPCs with VEGF shRNA, 61.1$±$7.2 cells 
per field (n$=$3)]. 
Second, I performed an in vitro cell migration assay, which clearly showed 
that the migratory ability of Alde-Low EPCs was suppressed under hypoxic 
conditions in the presence of SDF-1 in the EPCs that were transfected with CXCR4 
shRNA in comparison to the control Alde-Low EPCs [control Alde-Low EPCs: 
2.95$±$0.57 vs. Alde-Low EPCs with CXCR4 shRNA: 0.81$±$0.28-fold, P!<!0.01 
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(n$=$4);!Fig.!10!D]. 
Collectively, these data demonstrated that the expression of CXCR4 was a 
crucial factor in the successful repair of ischemic tissue by Alde-Low EPCs in this 
model. Taken together, the results indicate that the CXCR4/SDF-1 axis promoted the 
migration of EPCs to the ischemic tissue in our mouse model of skin flap ischemia. 
2.4. The effects of CXCR4 and VEGF gene overexpression in Alde-High EPCs 
I subsequently examined whether the capacity of Alde-High EPCs to 
regenerate ischemic tissue was improved after the transfection of CXCR4 or VEGF 
genes. Alde-High EPCs are useful for determining the key molecules that play a 
functional role in Alde-Low EPCs in wound repair. 
A reverse transcription-polymerase chain reaction (RT-PCR) clearly 
demonstrated the successful transfection of the target genes in Alde-High EPCs 
[CXCR4 overexpression: 18.6$±$3.1-fold expression (n$=$3); VEGF overexpression: 
16.4$±$2.0-fold expression (n$=$3);!Fig.!11]. An in vitro migration assay demonstrated 
that Alde-High EPCs, which were transfected with CXCR4, had a migratory ability 
that was similar to that of Alde-Low EPCs in the presence of SDF-1 under 5% O2 
conditions [Alde-Low EPCs, 2.95$±$0.57-fold; Alde-High EPCs, 0.82$±$0.18-fold; 
Alde-High EPCs with CXCR4 overexpression, 2.52$±$0.41-fold (n$=$3);!Fig.!12!A]. 
I then examined whether CXCR4 and VEGF-transfected Alde-High EPCs possessed 
the wound repair ability in our mouse model of skin flap ischemia. The sizes of the 
necrotic areas expressed as a percentage of the total flap area were as follows: 
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3.0%$±$5.1%, 38.9%$±$2.1% in Alde-High EPCs, 13.1%$±$5.1% in the Alde-High 
EPCs with CXCR4 gene transfection (P!<!0.01 vs. Alde-High EPCs), and 
21.4%$±$9.1% in the Alde-High EPCs with VEGF gene transfection (Fig.! 12! B,! C; 
n$=$3). These results clearly indicate that even when CXCR4 is expressed in Alde-
High EPCs, their capacity to repair the ischemic tissue was still inferior to that in 
Alde-Low EPCs. 
When I analyzed the number of transfected cells that were present at the site 
of the skin flap, I found that there were significantly more CXCR4-expressing Alde-
High EPCs than there were normal Alde-High EPCs. However, the number of 
migrated CXCR4-expressing Alde-High EPCs was still lower than the number of 
Alde-Low EPCs [Alde-Low EPCs, 76.8$±$5.9; Alde-High EPC, 11.3$±$10.9; CXCR4-
expressing Alde-High EPCs, 31.8$±$9.4 cells per field, P$<$0.05 (n$=$3); (Fig.! 12!D). 
These results indicate that the migratory effect related to CXCR4 was not sufficient 
to achieve the repair of the ischemic site, suggesting that there may be other factors 
involved in the wound repair ability of Alde-Low EPCs. 
3. Discussion 
EPCs that are harvested according to their cell surface markers show a 
hierarchy that is related to their growth activity [62]. Our group previously 
demonstrated that EPCs could be further separated into Alde-Low EPCs and Alde-
High EPCs based on their ALDH activity [18]. The ability of Alde-Low EPCs to 
repair ischemic tissue is superior to that of Alde-High EPCs; however, the molecular 
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mechanisms that prove these differences have not been elucidated. To characterize 
the differentiating states of each type of EPCs, I transfected Alde-High EPCs with 
MVs isolated from Alde-Low EPCs. As expected, the wounds in the mouse model of 
skin flap ischemia showed a full recovery after treatment with Alde-High EPCs that 
were transfected with MVs derived from Alde-Low EPCs. This finding suggests that 
the differentiating states of Alde-Low EPCs and Alde-High EPCs are highly similar 
and that the comparison of these EPCs would enable me to investigate the molecular 
mechanisms that underlie their association with recovery from ischemia. 
It has been reported that the direct intravenous injection of MVs derived from 
EPCs can improve revascularization after ischemic damage in a mouse model of 
hindlimb ischemia [63]. I also injected MVs (derived from Alde-Low EPCs) alone 
into the tail vein in a mouse model of skin flap ischemia. After treatment, however, 
the necrotic area did not significantly differ to that in the untreated control mice (data 
not shown). I cannot rule out the possibility that MVs alone are ineffective in 
repairing ischemic tissue, possibly because of the distance of the injection site from 
the site of skin flap. Further detailed analyses will be necessary to confirm the 
effectiveness of MVs by using a different ischemic model or a different 
transplantation method. In addition, it is speculated that the molecular composition of 
MVs derived from EPCs might change according to the physiological state. Indeed, 
the production of MVs was found to be enhanced after appropriate stimulation: in 
EPCs, hypoxia enhanced the production of MVs carrying miR-126 and miR-296 
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[64]. In this study, I investigated the effects of MVs released from Alde-Low EPCs 
under normal culture conditions. The results observed with MVs derived from Alde-
Low EPCs might have been different in association with neovessel formation or 
angiogenesis regulated by miRNA functions or others [65, 66], if I harvested MVs 
from EPCs cultured under different conditions. 
As described above, one of the key functions of EPCs in vivo is related to 
environmental stimuli, such as hypoxia. Under hypoxic conditions, EPCs, which are 
derived from the bone marrow, migrate through the peripheral blood to the sites of 
ischemia, where EPCs promote or directly contribute to the formation of new vessels 
[67, 68, 69]. Hypoxia-inducible factors, HIF-1α and HIF-2α, are known to respond to 
hypoxia, to form a heterodimer with Arnt and to transactivate the target genes [70]. It 
has been reported that these factors do not replenish each function, as shown by a 
knockout mouse study, and that the functional roles of these two factors are not fully 
understood [71]. In the present study, I found that HIF-1α and HIF-2α were both 
important in the transactivation of VEGF, whereas CXCR4 expression was 
profoundly regulated by HIF-2α in Alde-Low EPCs. Thus, the ability of Alde-Low 
EPCs that were transfected with HIF-2α shRNA to repair ischemic tissue was clearly 
reduced. Consequently, the size of the necrotic area was increased in comparison to 
the mice that were transfected with Alde-Low EPCs with HIF-1α shRNA. In fact, it 
has been shown that the expression level of SDF-1 that is secreted at the site of the 
skin flap is dependent on a low concentration of oxygen [34]. I also found that a high 
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level of SDF-1 was expressed in Alde-High EPCs plus MVs derived from Alde-Low 
EPCs. It suggests that in addition to inflammatory cells, SDF-1 receptor, CXCR4-
expressing EPCs would be the first candidate cells to be recruited to the ischemic 
sites in our mouse model of skin flap ischemia. Alternatively, the CXCR4/SDF-1 
axis might have survival/antiapoptotic effects on EPCs that enhance their engrafting 
capability in an autocrine manner [54]. 
Our group previously found that Alde-Low EPCs were incorporated into 
newly formed neovessels, indicating that transplanted EPCs contribute to the 
revascularization of ischemic tissue at the site of the skin flap rather than through the 
promotion of neoangiogenesis [18]. In the case of MSCs, we reported that, in 
addition to Alde-Low EPCs, transplanted AT-MSCs effectively repaired the 
perfusion of the blood flow in a mouse model of hindlimb ischemia, indicating that 
AT-MSCs promoted neoangiogenesis through a paracrine mechanism [58]. The 
migrated EPCs can secrete SDF-1 themselves to recruit the additional migration of 
CXCR4-positive EPCs or inflammatory cells to the site of ischemic tissues, 
suggesting that transplanted and migrated EPCs may function through a paracrine 
mechanism. 
Taken together, these results indicate that while both HIF-1α and HIF-2α have 
an important role in the recovery from ischemia, the role of HIF-2α in association 
with EPCs would be crucial during the process of ischemic tissue repair. Importantly, 
in the present study, I did not observe similar or increased numbers of migrated EPCs 
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at the site of the ischemic skin flap, even when CXCR4 or VEGF were overexpressed 
in the Alde-High EPCs. Nevertheless, the ischemic tissue fully recovered after the 
transplantation of the control Alde-Low EPCs or the MV-transfected Alde-High 
EPCs. Deregibus et al. described the contribution of MV-derived antiapoptotic 
protein Bcl-xL in target ECs [38], and hypothesized that an antiapoptotic mechanism 
would be involved in the migration of EPCs and in their survival at the site of 
ischemia. 
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Chapter IV. Microvesicles derived from Alde-Low EPCs support wound 
healing ability of AT-MSCs 
 
1. Purpose 
Stem cell-derived Microvesicles (MVs) are capable of carrying functional 
RNAs and proteins to target cells through the way of horizontal transfer. Alde-Low 
EPCs are known to be suitable for the treatment of ischemic tissue. Interestingly, the 
transfection of MVs derived from Alde-Low EPCs to non-functional Alde-High 
EPCs results in gain of function on wound repair.  
Mesenchymal stem cells (MSCs) are defined as multi-potent cells that can 
give rise to various kinds of differentiated cells, therefore thought to be useful for 
clinical therapy. 
The aim of this study was to evaluate whether MVs released from Alde-Low 
EPCs exert a homing effect of AT-MSCs in a mouse model of wound healing. 
Moreover, I studied which molecules are associated with the wound healing process 
in MV-transfected AT-MSCs. 
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2. Results 
2.1. Isolation of MVs derived from Alde-Low EPCs 
I have shown that MVs derived from Alde-Low EPCs have capacity to change 
the properties of Alde-High EPCs for healing the wound [54]. To investigate whether 
the effect of MVs derived from Alde-Low EPCs is applicable in other cell type, we 
performed transfection of MVs into AT-MSCs that have not shown the wound 
healing ability when AT-MSCs are injected intravenously in the mouse flap model.  
MVs were harvested from supernatant of Alde-Low EPCs culture by 
ultracentrifugation as described before [54], then isolated with cell sorter on the basis 
of surface markers for EPCs (CD31+, CD105+, CD45-) (Fig. 13A). It has been 
reported that MVs are released from the cell surface and are capable of transferring 
mRNAs and proteins to other cells [54, 72], therefore I evaluated Alde-Low EPCs 
derived MVs by characterizing mRNA that is known to be involved in cell migration 
and/or angiogenesis. As shown in Fig. 13B, most of mRNAs examined were 
expressed similarly as that of parent cell, Alde-Low EPCs, suggesting that the 
isolation of MVs succeeded  (Fig. 13B). In order to investigate the characteristics of 
AT-MSCs after receiving Alde-Low EPCs derived MVs, I performed co-culture of 
AT-MSCs and PKH26-labeled Alde-Low EPC-derived MVs. As shown in Fig.14 A, 
MVs were successfully internalized to target cell membrane after 12 hours 
incubation. To enrich the efficacy of the MVs in the AT-MSCs, MVs-incorporated 
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AT-MSCs was purified with cell sorter on the basis of fluorescein for PKH26 (Fig. 
14B), and used for further analysis. 
2.2. Characterization of AT-MSCs after receiving Alde-Low EPC-derived MVs 
I next examined whether AT-MSCs transfected with Alde-Low EPC-derived 
MVs still possess characteristics of AT-MSCs. Under the microscopic observation, 
fibroblast-like morphology of AT-MSCs was similar as that of MVs-transfected AT-
MSCs (Fig. 15). The analysis of MSC-specific cell surface markers (CD90+, CD105+, 
CD73+, CD14-, CD31-, CD45-, CD34-, CD271-, HLA-DR-) showed no differences 
between the control AT-MSCs and MVs-transfected AT-MSCs (Fig. 16) except 
CD34 expression. CD34 is a glycoprotein and known to be expressed on the surface 
of hematopoietic stem cells and immature state of endothelial cells. The CD34 
expression was slightly elevated in MVs-AT-MSCs. 
AT-MSCs are known to be multi-potent stem cells and able to differentiate 
into adipocytes, osteocytes and chondrocytes [58, 73, 74]. Thus, I next examined 
differentiation ability. As shown in Fig. 17, AT-MSCs transfected with MVs 
exhibited ability to differentiate adipocytes and osteocytes as similar as the control 
AT-MSCs.  
2.3. MVs derived from Alde-Low EPC alter mRNA and miRNA expression of 
AT-MSCs 
I then examined EPC and MSC related genes as well as miRNAs by real-time 
PCR. Previously I showed that chemokine receptor, CXCR4 and VEGF expression 
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was highly involved in the homing capacity of EPCs by intravenous injection [54]. 
As shown in Fig.18, the expression of CXCR4 chemokine receptor was significantly 
elevated in AT-MSCs transfected with MVs  (4.4 ± 0.9 fold increase, P < 0.01, n=3). 
On the other hand, the expression level of SDF-1, a ligand of CXCR4 showed no 
difference after transfection of MVs. The expression of VEGF showed slight increase  
(2.0 ± 0.5 fold increase, P < 0.05, n=3), and the expression of KDR, a receptor for 
VEGF was upregulated (2.8 ± 1.0 fold increase, P < 0.05, n=3) in MVs-AT-MSCs. 
The mRNA expression of chemokine, CCL2 and CCL5 that play an important role to 
recruit inflammatory cells at the sites of wound [50], was not different, although 
another chemokine IL-6 showed significant elevation (2.8 ± 0.9 fold increase, P < 
0.05, n=3) in MVs -AT-MSCs. The cell adhesion related genes play an important role 
to regulate the injected cells to reach to the target sites efficiently. The mRNA 
expression of adhesion molecules such as ColIV and VCAM-1, were neither different 
in MVs-AT-MSCs compared to the control. In addition, the mRNA expression of cell 
proliferation-related genes, such as TGF-β and b-FGF, were not different between 
them. Moreover, MVs contain miRNAs, which are small non-coding RNAs that 
function as guide molecules in RNA silencing and ~22 nucleotides in length [75]. In 
previous reports demonstrated that miR-126, miR-296 are regulated mobilization and 
migration of bone marrow-derived mononuclear cells as well as angiogenesis process 
[76, 77]. Chen et al. demonstrated that MSCs transfected with miR-126 survived a 
long time and effectively expressed miR-126 for at least six weeks at the injected 
area in myocardial infarction mouse model. The intra-myocardial injection of MSCs 
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overexpressing miR-126 into ischemic myocardium significantly enhanced the vessel 
density, resulting in the improvement of angiogenesis [76]. Consistent with these 
reports, I found that miR-126 and miR-296 were highly expressed in MV-transfected 
AT-MSCs compared with the control AT-MSCs (P<0.01, n=3 in each) (Figure 19).  
Previously, I demonstrated that hypoxia inducible factors (HIFs), especially 
HIF-2α is highly expressed in Alde-Low EPCs and is responsible for cell migration 
toward the wound sites thorough the positive regulation of CXCR4 expression [54]. 
There was no significant difference of HIF-2α expression in MVs-AT-MCSs 
compared to the control at mRNA and protein levels (data not shown), suggesting the 
expression of CXCR4 in MVs transfected AT-MSCs is not depend on HIF-2α 
regulation.  
Collectively, these data suggested that MVs derived from Alde-Low EPCs 
were capable to alter gene expression profile in AT-MSCs but different from the case 
of Alde-High EPCs and miRNAs shuttled by MVs contributed to AT-MSC’s 
regenerative potential. 
2.4. MVs derived from ALDH-Low EPCs enhance migration ability of AT-
MSCs 
 It has been shown that AT-MSCs exhibited low cell migratory ability and only 
cure wound when injected at injured area directory [78]. I then investigated the 
capacity of AT-MSCs in wound healing while injecting directly to skin of ischemia 
model.  As shown in Fig. 20, mouse flap model clearly showed that the area of 
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necrosis was smaller in the mice injected with AT-MSCs when comparing with mice 
injected PBS (necrotic area: control PBS: 59.8% ± 6.6%, AT-MSCs: 16.2% ± 9.5%). 
On the other hand, I have previously reported that CXCR4 is crucial factor for the 
migration of Alde-Low EPCs at the site of wound [54]. To characterize the functional 
role of AT-MSCs with MVs, I performed in vitro scratch assay that can mimic cell 
migration during wound healing [59]. As shown in Fig. 21A, in vitro scratch assay 
clearly showed higher migratory ability in MVs-transfected AT-MSCs compared to 
the control AT-MSCs (% migration distance: AT-MSCs with MVs-derived from 
Alde-Low EPCs, 402.0 % ± 51.2 %; control, 157.2 % ± 49.4 %; P < 0.001, n=3).  
 Then I investigated whether Alde-low EPC-derived MVs could effect on the 
proliferation activity in AT-MSCs. As shown in Fig. 21 B, no significant difference 
was observed in the cell growth between MVs transfected AT-MSCs and the control 
AT-MSCs.   
Hence, these results suggested that AT-MSCs specifically acquired migration 
ability but not proliferation ability by MVs derived from Alde-Low EPCs. 
2.5. AT-MSCs gained the ability to repair wound by transfection of MVs 
derived from Alde-Low EPCs   
I next examined whether MVs-AT-MSCs possess the capacity to impair the 
wound healing process in the mouse flap model [54].  
In order to assess migratory ability in vivo, I analyzed the localization of AT-
MSCs at the wound sites after intravenous injection. As shown in Fig. 22A, 24 hours 
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later from the injection through tail vein, PHK67 (green fluorescent)-labeled AT-
MSCs with MVs were detected at wound site whereas the control AT-MSCs were 
barely detected at the site. Subsequently, in order to verify whether inflammatory 
cells were recruited at the wound site following the AT-MSC arrival, the number of 
CD45+ cells was scored on day 3 after the injection. As shown in Fig. 22 B, C, 
significantly higher number of CD45+ cells were observed at the wound site in the 
MVs-AT-MSCs compared to the control AT-MSCs (CD45+cell number/field: AT-
MSCs, 28.7 ± 1.8; AT-MSCs with MVs-derived from Alde-Low EPCs, 40.1 ± 3.0, P 
< 0.01, n=3). 
Moreover, in vivo wound healing efficiency was evaluated by measuring size 
of necrotic area on day 7 after the injection. As shown in Fig. 22D, AT-MSCs with 
MVs exhibited high capacity to repair the wound compared to the control AT-MSCs 
(necrotic area: control PBS: 72% ± 4.6%, Alde-Low EPCs: 9.7% ± 5.7%, AT-MSCs, 
67.0% ± 0.1%; AT-MSCs with MVs-derived from Alde-Low EPCs, 10.4 % ± 8.6%, 
P < 0.05, n=3).  
Collectively, these results indicate that MVs derived from Alde-Low EPCs are 
capable for changing the properties of AT-MSCs to possess the homing ability to 
migrate to the wound site in vivo (Fig. 23). 
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3. Discussion 
Here, I show that MVs from EPCs derived from UCB provide an important 
potential as a therapeutic tool for AT-MSCs. Importantly, MVs possess the abilities 
to compensate and change the properties in the recipient cells by delivering their 
bioactive factors, therefore these effects could expand a novel therapeutic strategy. 
Our group previously demonstrated that EPCs are subdevided into two 
populations based on their ALDH activity, such as Alde-Low and Alde-High EPCs 
[18]. In addition, we showed that Alde-Low EPCs efficiently repairs ischemic tissues 
because CXCR4 and VEGF are highly expressed under hypoxic conditions compared 
to Alde-High EPCs [18].  In fact, transfection of MVs isolated from Alde-Low EPCs 
was effective to change the properties of Alde-High EPCs to improve the wound 
healing process [54]. 
MSCs themselves are known to release MVs that mimic the beneficial effects 
of target cells, suggesting those MVs derived from MSCs may induce various kinds 
of regenerative functions of MSCs [79, 80]. 
In the present study, I performed transfection of MVs derived from Alde-Low 
EPCs into AT-MSCs. AT-MSCs that was originally unable to repair the wound when 
transplanted intravenously (Fig. 22D) became to migrate at the wound sites after the 
incorporation of MVs derived from Alde-Low EPCs. These facts suggested that the 
effect of MVs would be conserved and applicable to other type of stem cells other 
than AT-MSCs.  
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Consistent with previous reports, AT-MSCs are able to repair the wound when 
they are directly transplanted to the wound sites. Subsequently, AT-MSCs secrete 
chemokines (such as SDF1, CCL5) and CD45+ inflammatory cells including 
monocytes and lymphocytes are recruited to promote the first step of wound healing 
[81]. Migration ability of AT-MSCs is defective in the wound healing process when 
intravenous transplantation was performed. In this study, I found there were no 
obvious differences on the expression levels for SDF-1 and CCL5 between the 
control AT-MSCs and MVs-transfected AT-MSCs  (Fig. 18). Of note, significant 
upregulation of CXCR4 was observed in AT-MSCs with MVs derived from Alde-
Low EPCs (Fig. 18). In accordance with the result, the migratory ability of AT-MSCs 
with MVs was also enhanced in vitro compared to the control  (Fig. 21A). It has been 
reported that SDF-1 is secreted at the site of skin flap dependent on degree of low 
oxygen tension [34]. Thus, CXCR4 highly-expressed AT-MSCs may be attracted and 
migrated to the wound sites where the expression of SDF-1 is upregulated.  
Gheisari et al. reported that CXCR4 and CXCR7, which is another SDF-1 
receptor, were overexpressed in bone marrow MSCs, and those cells were injected in 
a mouse model of cisplatin-induced acute kidney injury. They found overexpression 
of CXCR4 and CXCR7 in BM-derived MSCs could not improve the homing and 
therapeutic potentials of those cells [82]. In contrast, other groups reported that 
autologus MSCs transplantation showed renoprotective effects [83]. These 
controversies might be explained by differences in the protocol of cell 
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transplantation, the animal strain, and type and severity of kidney injury. This study 
evokes one important mechanism on AT-MSCs homing in wound healing process, 
however it also suggests a measurement in the same conditions would be necessary 
to clarify the mechanism for clinical use of AT-MSCs. 
It is well known that MSCs secrete various kinds of cytokines and growth 
factors. IL-6 is one of secreted factors from MSCs, and reported that inhibit 
lymphocyte apoptosis via direct interactions each other [84]. Pricola et al. have 
reported that IL-6 maintains the proliferative and undifferentiated states of bone 
marrow-derived MSCs. They also suggested that IL-6 has potency to protect bone 
marrow-derived MSCs from apoptosis and increases in vitro wound healing activity 
[84].  In the present study, significant increase of IL-6 expression was observed in 
AT-MSC transfected MVs derived from Alde-Low EPCs (Fig. 18), suggesting that 
upregulated expression of IL-6 in MVs-AT-MSCs might act in a paracrine fashion to 
impair the wound healing process. 
It has been reported that MVs are capable of transferring not only mRNAs but 
also miRNAs to other cells [85, 86, 87]. Micro-RNAs are small noncoding RNA 
(~22 nucleotides) and known to be able to regulate the gene expression at a post-
transcriptional level through the translational inhibition and/or destabilization of 
targeted mRNAs [88, 89]. Several lines of evidences have shown that miRNAs are 
involved in angiogenesis, cell survival and CXCR4 regulation in ischemic tissue. 
Thus, I examined expression of miRNAs in MVs-transfected AT-MSCs, and found 
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significant increase of miR-126, miR-296 (Fig. 19). Thus, it is conceivable that the 
improved wound healing with MVs-transfected AT-MSCs was achieved by several 
molecular mechanisms such as migration factors and miRNAs. 
It is reported that appropriate stimulus such as hypoxia enhance the production 
of MVs carrying miR-126 and miR-296 from EPCs [90]. In this study, I investigated 
the effects of MVs released from Alde-Low EPCs without any stimulus. Thus, it may 
be intriguing issue to investigate a different effect of MVs derived from Alde-Low 
EPCs cultured in hypoxic condition.  
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Chapter V. Conclusion and Perspective  
Conclusion 
In my studies, I proved the crucial role of CXCR4 expressed on Alde-Low 
EPCs in the process of ischemic tissue repair. While CXCR4 is profoundly regulated 
by HIF-2α, another candidate gene, VEGF is regulated by HIF-1α and HIF-2α in 
Alde-Low EPCs. To specify the target molecules in each step of recovery from 
ischemia, further investigation will be needed to clarify the complicated mechanisms 
that underlie the tissue repair process. The precise analysis of the function of EPCs 
would provide new evidence that could be applied to stem cell therapy for patients 
with tissue ischemia of various etiologies. 
Moreover, I provided the possibility that Alde-Low EPCs-derived MVs may 
be useful tool to change the properties of AT-MSCs into applicable for intravenous 
and/or intra-arterial injection treatment. I still do not know whether MVs derived 
from Alde-Low EPCs would be effective for the migration of other type of stem 
cells. Further studies would be necessary to prove the key molecules including 
CXCR4 associated with the homing of AT-MSCs as well as other type of MSCs. 
These results might bring therapeutic breakthrough for a difficult disease to treat, for 
example, long standing ulcers with dense scar tissue. 
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Perspective 
Recently, a number of studies about EPCs are increasing due to function of 
EPCs in neovascularization. Moreover, EPCs can be applied to treat disease related 
to ischemia. It is required a specific marker to isolate functional EPCs. Our group 
reported that ALDH activity is a useful marker to isolate functional EPCs (Alde-Low 
EPCs) which show migration ability as well as facilitation wound healing in the 
mouse flap model. CXCR4, a chemokine receptor which is directly regulated by HIF-
2α, plays important role in EPC migration ability to wound site. Knockdown of 
CXCR4 expression in Alde-Low EPCs impaired wound healing ability. Of note, 
cancer cells expressed high level of CXCR4 mRNA. Thus, understanding of CXCR4 
function can support to control EPC therapy as well as contribute to study about 
cancer cell metastasis. The overexpression of CXCR4 in Alde-High EPCs (non-
functional EPCs) improves their migration, resulting in wound healing. To enhance 
the effect of the improvement of migration ability, microvesicles derived from Alde-
Low EPCs might be a good candidate to change characteristics of recipient cells. My 
data demonstrated that MVs derived from Alde-Low EPCs can improve migration of 
Alde-High EPCs and AT-MSCs by upregulated genes expression related to 
migration, angiogenesis, cell survival, adhesion and proliferation. Further 
examination of MVs function is needed to clarify the mechanism of genes delivery as 
well as tumorgenesis. Understanding of MVs function can build a foundation to other 
research fields such as cell biology, cancer cell and drug delivery. 
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Figures and legends 
 
Figure 1. EPCs contribute to the repair of injured vessels 
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Figure 2. Microvesicle budding from cytoplasmic membrane.   
Budding process takes place at unique locations on the cell membrane that are 
enriched with specific lipids, mRNAs, miRNAs and proteins reflecting their cellular 
origin. 
 
  
Figure 3. Isolation protocol of microvesicles 
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Figure 4. Characteristic of MVs derived from Alde-Low EPCs.  
(A) MVs derived from Alde-Low EPCs were isolated by FACS after centrifugation. 
(B) The analysis of mRNA levels of the indicated genes in MVs and parental cells by 
an RT-PCR. c, Alde-Low EPCs; m, MVs derived from Alde-Low EPCs. (C) MVs 
derived from Alde-Low EPCs were stained with PKH-26 (red fluorescent) and 
transfected to cells. After 12$h, the cells were observed under fluorescence 
microscope. Scale bar: 200$µm.  
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Figure 5. Angiogenic gene expression of Alde-High EPCs transfected MVs 
derived from Alde-Low EPCs 
CXCR4, VEGF, SDF-1, ColIV, and VCAM-1 mRNA expression were analyzed in 
Alde-High EPCs that were transfected with MVs (black bar) in comparison to Alde-
High EPCs (white bar) under normoxic conditions. The expression level detected in 
Alde-High EPCs was normalized to a value of 1 as the standard for each factor. 
*P!<!0.05, **P!<!0.01.  
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Figure 6. MVs derived from Alde-Low EPCs can improve the in vivo angiogenic 
activity of Alde-High EPCs 
(A) Skin incisions were created on the dorsal skin of mice. PBS alone, Alde-Low 
EPCs, Alde-High EPCs, or Alde-High EPCs with MVs were injected to the mice. 
The effects of the EPCs in the recovery from ischemia were analyzed on day 7 after 
surgery. (B) The necrotic regions in the four different types of mice (n$=$3 in each) 
were measured. Note that the area of necrosis in the mice that were injected with 
Alde-High EPCs with MVs was similar to that in mice that were injected with Alde-
Low EPCs. *P!<!0.05, **P!<!0.01. 
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Figure 7. Analysis of the involvement of HIF-1α and HIF-2α in the repair of 
ischemic tissue of Alde-Low EPCs shRNA HIFs. 
(A, B) The protein expression levels of HIF-1α (A) and HIF-2α (B) were analyzed by 
western blotting in mock Alde-Low EPCs (control), Alde-Low EPCs transfected with 
shHIF-1α RNA, or Alde-Low EPCs transfected with shHIF-2α RNA. The control 
cells and the two types of transfected cells (#1 and #2) were treated with (+) or 
without (−) 100$µM DFO for 6$h before the analysis. (C) The mRNA expression level 
of the indicated genes in the Alde-Low EPCs, the Alde-Low EPCs with HIF-1α 
shRNA, and the Alde-Low EPCs with HIF-2α shRNA were measured using an RT-
PCR. Note that the CXCR4 expression was downregulated by HIF-2α shRNA, but 
not by HIF-1α shRNA. *P!<!0.05, **P!<!0.01. 
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Figure 8. The involvement of HIF-1α and HIF-2α in in vivo angiogenesis ability 
of Alde-Low EPCs shRNA HIFs 
(A) Skin incisions were created on the dorsal skin of mice. PBS, mock Alde-Low 
EPCs, Alde-Low EPCs with HIF-1α shRNA, or Alde-Low EPCs with HIF-2α 
shRNA were injected into the mice. The effects of the EPCs on the repair of ischemic 
tissue were analyzed on day 7 after surgery. (B) The necrotic regions in the four 
types of mice (n$=$3 in each) were measured. Note that in the ability to repair 
ischemic tissue was lost in mice that were injected with Alde-Low EPCs with HIF-2α 
shRNA. *P!<!0.05, ** P!<!0.01.  
! 57!
(C) The number of migrated GFP+ cells was measured. Note that the number of GFP+ 
cells at the site of skin flap was decreased in the mice that were injected with Alde-
Low EPCs with HIF-2α shRNA. *P!<!0.05, **P!<!0.01.  
(D) A CHIP assay was performed to examine binding to the hypoxia response 
element (HRE) region of the CXCR4 promoter under normoxic (N) and hypoxic 
conditions (H). Note that HIF-2α, but not HIF-1α, binds to CXCR4 promoter under 
both conditions. CHIP, chromatin immunoprecipitation; DFO, desferrioxamine; GFP, 
green fluorescent protein; HIF, hypoxia-inducible factor; shRNA, short hairpin RNA. 
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Figure 9.  Analysis of the expression of CXCR4 and VEGF genes in Alde-Low 
EPCs shRNA CXCR4 or VEGF 
 The mRNA expression levels of the indicated genes in mock Alde-Low EPCs, Alde-
Low EPCs with VEGF shRNA, or Alde-Low EPCs with CXCR4 shRNA were 
analyzed by a qPCR [white bar: normoxic conditions; black bar: hypoxic conditions 
(1% O2 for 6$h)]. The expression levels that were detected in the mock Alde-Low 
EPCs under normoxic conditions were normalized to a value of 1 as the standard for 
each gene. **P!<!0.01.  
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Figure 10. Analysis of the involvement of CXCR4 and VEGF in the repair of 
ischemic tissues of Alde-Low EPCs knockdown CXCR4 or VEGF genes. 
(A) Skin incisions were created on the dorsal skin of mice. Mock Alde-Low EPCs, 
Alde-Low EPCs with VEGF shRNA, or Alde-Low EPCs with CXCR4 shRNA were 
injected into the mice. The effect of EPCs on the repair of ischemic tissue was 
analyzed on day 7 after surgery. (B) The necrotic regions in the mice that were 
injected with three different types of EPCs (n$=$3 in each) were measured. *P!<!0.05, 
**P!<!0.01.  
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(C) The number of migrated GFP-labeled Alde-Low EPCs at the site of the skin flap 
was counted. **P!<!0.01. (D) An in vitro transwell culture assay was performed to 
analyze in vitro migration. The migratory ability of Alde-Low EPCs with CXCR4 
shRNA was analyzed and compared with that of the mock Alde-Low EPCs in the 
presence of SDF-1. White bar, 20% O2 without SDF-1; white striped bar, 20% O2 
with SDF-1; black solid bar, 5% O2 without SDF-1; gray bar, 5% O2 with SDF-1. 
*P!<!0.05, **P!<!0.01. qPCR, quantitative PCR. 
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Figure 11.  Analysis of angiogenic gene expression of Alde-High EPCs with 
CXCR4 or VEGF overexpression.  
The mRNA expression levels of the indicated genes in mock Alde-Low EPCs 
(control), mock Alde-High EPCs (control), Alde-High EPCs-CXCR4 overexpression, 
and Alde-High EPCs-VEGF overexpression were analyzed using a qPCR [white bar: 
normoxic conditions; black bar: hypoxic conditions (1% O2 for 6$h)]. The expression 
level of the mock Alde-Low EPCs under normoxic conditions was normalized to a 
value of 1 as the standard for each gene. **P!<!0.01.  
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Figure 12. Wound healing in vitro and in vivo in Alde-High EPCs transfected 
CXCR4 or VEGF genes 
(A) The migration ability of EPCs was analyzed with an in vitro transwell culture 
assay. The migratory ability of Alde-Low-EPCs (positive control), mock Alde-High 
EPCs, or Alde-High EPCs with CXCR4 overexpression in the presence of SDF-1 
was investigated. White bar, 20% O2 without SDF-1; striped bar, 20% O2 with SDF-
1; black bar, 5% O2 without SDF-1; gray bar, 5% O2 with SDF-1. *P!<!0.05.  
(B) Skin incisions were created on the dorsal skin. Alde-Low EPCs, mock Alde-High 
EPCs, Alde-High EPCs with CXCR4 overexpression, or Alde-Low EPCs with VEGF 
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overexpression were injected into the mice. The effects of EPCs on the repair of 
ischemic tissue were analyzed on day 7 after surgery.  
(C) The necrotic regions in the four types of mice (n$=$3, each) were measured. Note 
that the recovery of ischemic tissue was superior in mice that were injected with 
Alde-High EPCs with CXCR4 overexpression to that in mice that were injected with 
Alde-High EPCs. *P!<!0.05, **P!<!0.01. (D) The number of migrated cells at the site 
of the skin flap was measured. Note the difference in the number of migrated cells in 
the mice that were injected with Alde-High EPCs with CXCR4 overexpression and 
the mice that were injected with Alde-Low EPCs. *P!<!0.05. 
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Figure 13. Characteristics of specific cell surface marker and gene expression of 
MVs derived from Alde-Low EPCs.  
(A). Representative FACS analysis of the Alde-Low EPCs and their MVs at 37°C. 
MVs derived from Alde-Low EPC are positive for CD31, CD105 and negative for 
CD45. (B). Analysis of mRNA levels for some selected genes in MVs and parental 
cells. All transcripts were analyzed using real-time polymerase chain reaction (PCR). 
PCR products were visualized on 2% agarose gel.  
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Figure 14. Characteristics of the internalize ability of MVs derived from Alde-
Low EPCs. 
(A). Alde-Low EPCs derived MVs were stained by PKH26 (Red fluorescent –Sigma) 
and transfected to AT-MSCs. After 12 h of incubation, cells were visual under 
fluorescent microscope. Bar indicates 200 µm. (B). FACS analysis of red fluorescent 
in transfected cells. 
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Figure 15. Comparison of morphology between AT-MSCs and AT-MSCs 
transfected MVs derived from Alde-Low EPCs 
AT-MSCs and AT-MSCs transfected MVs showed the spindle-shaped and fibroblast-
like morphology. Scale bar indicates 200 µm. 
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Figure 16. Comparison of cell surface markers between AT-MSCs and AT-
MSCs transfected MVs derived from Alde-Low EPCs 
 FACS analysis of cell surface markers on AT-MSCs and AT-MSCs transfected 
MVs. Both were analyzed cell surface markers for CD14, CD31, CD45, CD90, 
CD105, CD34, CD73, CD271, HLA-DR.  
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Figure 17. Comparison of differentiation capacity between AT-MSCs and AT-
MSCs transfected MVs derived from Alde-Low EPCs 
Each type of MSCs was analyzed to determine adipogenic and osteogenic 
differentiation potential. Adipogenesis was examined by the detection of lipid 
vacuoles by Oil Red O staining without induction (upper column) or with induction 
(below column), scale bar indicates 50µm. Osteogenesis was analyzed by Alizarin 
Red S staining without induction (upper column) or with induction (below column), 
scale bar indicates 200µm. There was no difference in AT-MSCs and AT-MSCs 
transfected MVs derived from Alde-Low EPCs.  
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Figure 18. The expression of genes related to migration, angiogenesis, adhesion 
of AT-MSCs and AT-MSCs transfected MVs. 
AT-MSCs were incubated with Alde-Low EPCs derived MVs for 12 h, then total 
mRNAs were extracted using Isogen following the procedure by the manufacturer. 
The gene expression profiles were analyzed by real-time polymerase chain reaction 
(ABI 7500Fast Real-time PCR system). White bar indicated AT-MSCs mock, black 
bar indicated AT-MSCs transfected with MVs. The expression levels AT-MSCs 
were normalized to a value of 1 as the standard for each factor. * P<0.05, ** P<0.01. 
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Figure 19. miRNA expression of AT-MSCs and AT-MSCs transfected MVs 
derived from Alde-Low EPCs 
miR-126, miR-296 expression levels were upregulated in AT-MSCs transfected 
EPC-MVs in the normoxic condition. MVs derived from Alde-Low EPCs were 
incubated with AT-MSCs for 12 h. miRNAs were isolated and cDNAs were 
synthesized by using Taqman miRNA reverse transcription kit following the 
procedure suggested by the manufacturer. White bar indicate AT-MSCs, black bar 
indicate AT-MSCs treated EPC-MVs. The expression levels seen in AT-MSCs were 
normalized to a value of 1 as the standard for each factor. **P < 0.01. 
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Figure 20. Mouse flap model by local injection of AT-MSCs 
Skin incisions were created on the dorsal surfaces of mice, and control PBS and AT-
MSCs were injected directly to skin. The effectiveness of PBS, AT-MSCs to recover 
tissue from ischemia was examined on day 7 following surgery. The necrotic regions 
in the 2 types of mice (n=3 in each) were measured. Note that the area of necrosis 
was smaller in the mice injected with AT-MSCs when comparing with mice injected 
PBS. The graph showed % of necrotic area, white bar indicated PBS injection, white 
bar indicates PBS, black bar indicates AT-MSCs injection. *P<0.05. 
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Figure 21. Alde-Low EPCs derived MVs enhanced the in vitro migration of AT-
MSCs.  
(A) AT-MSCs were plated to 100% confluent in 4-wells dish, then treated with 
10µg/mL mytomicin C for 3 h in order to inhibit the proliferation of the cells. After 
washing 3 times by PBS, the wound 1mm in diameter was made by scraping with a 
200µm Fisher-brand pipette tip. Cells were washed with PBS and imaged and 
subsequently incubated with MVs derived from Alde-Low EPCs. On the left side, the 
representative photograph of the wound edge at 0h and 16 h after incubating MVs 
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derived from Alde-Low EPCs (bar = 200µm). The migration distances were measure 
by software Image J. On the right side, migration distance (µm) of the AT-MSCs 
treated EPC-MVs significantly greater than the control AT-MSCs. *** P < 0.001. 
(B) AT-MSCs treated with EPC-MVs and control AT-MSCs were plated at 20,000 
cells/dish, then cell counting was performed everyday until day 10. The left side 
shows growth curve. The right side shows doubling time of the cells. No significant 
different of the proliferation were noticed (white bar indicates AT-MSCs, black bar 
indicates AT-MSCs transfected EPC-MVs). 
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Figure 22. Alde-Low EPCs derived MVs enhanced the in vivo angiogenesis of 
AT-MSCs. 
(A) Skin incisions were created on the dorsal surfaces of mice, then control AT-
MSCs and ATMSCs treated with Alde-Low EPC-MVs were injected through tail 
vein (n=3). MVs derived from Alde-Low EPCs were stained by PKH67 (Green 
fluorescent) before the incubation with AT-MSCs. After 24 h injection of AT-MSCs 
or AT-MSCs treated EPC-MVs, lectin (red fluorescent) was injected through tail 
vein, then the back skin were collected and the frozen tissue sections were prepared. 
The fluorescent signals were detected under microscope. (Bar =100µm).  
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(B, C) After 3 days of cell-injection, the back skins of mice were prepared for 
making frozen sections. Immunohistochemistry was performed to detect CD45 
positive cells. The graph shows the number of CD45+ cells of AT-MSCs and AT-
MSCs treated with EPC-MVs. (D) The effectiveness of PBS, Alde-Low EPCs, AT-
MSCs and AT-MSCs treated with EPC-MVs on the tissue recovery from ischemia 
was examined on day 7 following surgery. The necrotic regions in each 4 types of 
mice (n=3) were measured. Note that the area of necrosis was significantly smaller in 
the mice injected with AT-MSCs transfected EPC-MVs when comparing with mice 
injected AT-MSCs. The graph shows % of necrotic area, grey bar indicates PBS 
injection, striped bar indicates Alde-Low EPCs injection, white bar indicates AT-
MSCs injection and black bar indicates AT-MSCs transfected MVs. *P<0.05, 
**P<0.01. 
!
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Fig. 23. Scheme of the Alde-Low EPCs derived MVs function to support wound 
healing of AT-MSCs 
A schematic drawing review the hypothesis of the function of MVs derived from 
Alde-Low EPCs to enhance migratory ability of AT-MSCs, resulting in wound 
healing. 
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